IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGIC MEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Rish Pai  1     Gert De Hertogh  2     Walter Reinisch  3     Noam Harpaz  4     Brian Feagan  5     Noah Agada  6     Paul Pollack  6     Lai Shan Chan  7     Marijana Protic     Fernando Magro    
1 Mayo Clinic,Indianapolis,United States
2 University Hospitals Leuven,Leuven,Belgium
3 Medical University Vienna,Vienna,Austria
4 Icahn School of Medicine,New York,United States
5 Robarts Clinical Trials Inc.,Ontario,Canada
6 Eli Lilly and Company,Indianapolis,United States
7 Eli Lilly and

Session
IBD (Posters)

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing